Study of HPV Specific Immunotherapy in Patients With HPV Associated Head and Neck Squamous Cell Carcinoma

Study Description

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

This is a Phase I/IIa, open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3112 DNA vaccine delivered by Electroporation to subjects with HPV associated head and neck squamous cell cancer.

Condition or disease	Intervention/treatment	Phase
Head and Neck Squamous Cell Cancer	Biological: 1.1 mL of INO-3112 (VGX-3100 + INO-9012) delivered IM via EP with CELLECTRA-5P device	Phase 1; Phase 2

Detailed Description:

This is a Phase I/IIa, open-label, study to evaluate the safety, tolerability, and immunogenicity of INO-3112 [6 mg of VGX-3100 (2 separate DNA plasmids respectively encoding E6 and E7 proteins of HPV 16 and HPV 18) and 1 mg of INO-9012 (DNA plasmid encoding human interleukin 12)] delivered by electroporation (EP) in up to 25 (twenty five) subjects with HPV positive head and neck cancer. The immunotherapy will be studied in following two groups of subjects:

1. Subjects who will receive immunotherapy before and after definitive surgery (Cohort I)
2. Subjects who will receive immunotherapy at least 2 months after chemoradiation therapy (Cohort II).

Study Design

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	22 participants
Allocation:	Non-Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Prospective Study of HPV Specific Immunotherapy in Patients With HPV Associated Head and Neck Squamous Cell Carcinoma (HNSCCa)
Study Start Date :	June 2014
Actual Primary Completion Date :	January 23, 2017
Actual Study Completion Date :	November 2017

Arms and Interventions

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Surgery Cohort; 1.1 mL of INO-3112 (VGX-3100 and INO-9012) delivered IM via CELLECTRA-5P device	Biological: 1.1 mL of INO-3112 (VGX-3100 + INO-9012) delivered IM via EP with CELLECTRA-5P device; Eligible subjects who consent to participate in the study will receive a 1.1 mL IM injection of INO-3112 (VGX-3100 and INO-9012) via IM+EP with CELLECTRA®-5P. All subjects will receive a total of 4 doses of immunotherapy; Other Names: VGX-3100; INO-9012
Chemoradiation; 1.1 mL of INO-3112 (VGX-3100 and INO-9012) delivered IM via CELLECTRA-5P device	Biological: 1.1 mL of INO-3112 (VGX-3100 + INO-9012) delivered IM via EP with CELLECTRA-5P device; Eligible subjects who consent to participate in the study will receive a 1.1 mL IM injection of INO-3112 (VGX-3100 and INO-9012) via IM+EP with CELLECTRA®-5P. All subjects will receive a total of 4 doses of immunotherapy; Other Names: VGX-3100; INO-9012

Outcome Measures

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Safety and Tolerability of INO-3112 (VGX-3100 and INO-9012) delivered via IM+EP [ Time Frame: 6 months post last dose ]

   Evaluate the safety and tolerability of immunotherapy with INO-3112 (VGX-3100 and INO-9012) when delivered intramuscularly followed by electroporation with CELLECTRA®-5P in patients with HPV associated Head and Neck Cancer.

   Adverse events will be measured

Secondary Outcome Measures :

1. Immunogenicity of INO-3112 (VGX-3100 and INO-9012) delivered via IM+EP [ Time Frame: 6 months post last dose ]

   Evaluate the cellular and humoral immune responses to immunotherapy with INO-3112 (VGX-3100 and INO-9012) delivered by electroporation with CELLECTRA®-5P in patients with HPV associated Head and Neck cancer

   Measure HPV 16 and HPV 18 E6 E7 Ig levels, IFN-γ-secreting cells and cytotoxic T cells in response to HPV specific immunotherapy.

Other Outcome Measures:

1. Anti-tumor effects [ Time Frame: 6 months post last dose ]
   Anti-tumor effects by investigator's clinical assessment
2. Progression Free Survival [ Time Frame: 6 months post last dose ]
   Progression Free Survival

Eligibility Criteria

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

1. Signed and dated written Ethics Committee approved informed consent.
2. Age ≥18 years.

3. Histologically confirmed HPV-positive (as assessed by p16 IHC or oncogenic HPV ISH or PCR) mucosal squamous cell head and neck cancer:

   • For pre-surgical subjects, p16 positivity must be confimed prior to first dose
   • For subjects post-chemoradiation, HPV 16 and HPV 18 positivity must be confirmed prior to first dose.
4. Adequate bone marrow, hepatic, and renal function. ANC (Absolute Neutrophil Count) ≥ 1.5x109 cell/ml, platelets ≥75,000 cells/mm3, hemoglobin ≥9.0 g/dL, concentrations of total serum bilirubin within 1.5 x upper limit of normal (ULN), AST, ALT within 2.5x institutional ULN, CPK within 2.5 x ULN.
5. ECOG (Eastern Cooperative Oncology Group) performance status of 0-1.

Exclusion Criteria:

1. Anticipated concomitant immunosuppressive therapy (excluding non-systemic inhaled, topical skin and/or eye drop-containing corticosteroids).
2. Any concurrent condition requiring the continued use of systemic steroids (>10 mg prednisone or equivalent per day) or the use of immunosuppressive agents. All other corticosteroids must be discontinued at least 4 weeks prior to Day 0 of treatment.
3. Administration of any vaccine within 6 weeks of enrollment.

Contacts and Locations

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104

Sponsors and Collaborators

Inovio Pharmaceuticals

University of Pennsylvania

Investigators

Study Director:	Ildiko Csiki, MD	Inovio Pharmaceuticals

More Information

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Additional Information:

Sponsor's Website 

Publications:

Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC, Giffear M, Pankhong P, Khan AS, Broderick KE, Knott C, Lin F, Boyer JD, Draghia-Akli R, White CJ, Kim JJ, Weiner DB, Sardesai NY. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med. 2012 Oct 10;4(155):155ra138. doi: 10.1126/scitranslmed.3004414.

Diehl MC, Lee JC, Daniels SE, Tebas P, Khan AS, Giffear M, Sardesai NY, Bagarazzi ML. Tolerability of intramuscular and intradermal delivery by CELLECTRA(®) adaptive constant current electroporation device in healthy volunteers. Hum Vaccin Immunother. 2013 Oct;9(10):2246-52. doi: 10.4161/hv.24702. Epub 2013 Jun 4.

Responsible Party:	Inovio Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT02163057 History of Changes
Other Study ID Numbers:	HPV-005
First Posted:	June 13, 2014
Last Update Posted:	July 20, 2018
Last Verified:	July 2018

Keywords provided by Inovio Pharmaceuticals:

Head and neck squamous cell cancer; Papillomavirus

Additional relevant MeSH terms:

Carcinoma, Squamous Cell; Head and Neck Neoplasms; Neoplasms, Squamous Cell; Carcinoma	Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site